Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 1051-1058

  Cantarini, Luca ^a   Lucherini, O M ^a   Cimaz, R ^b   Baldari, C T ^a   Bellisai, F ^a   Rossi Paccani, S ^a   Laghi Pasini, F ^a   Capecchi, P L ^a   Sebastiani, G D ^c   Galeazzi, M ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Colchicine resistance; Etanercept; Idiopathic recurrent pericarditis; TNFRSF1A mutation; Tumor necrosis factor receptor 1 associated periodic syndrome

Indexed keywords

COLCHICINE; ETANERCEPT; GENOMIC DNA; INDOMETACIN; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DNA SEQUENCE; DRUG RESPONSE; EXON; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOTE; HUMAN; HUMAN CELL; IDIOPATHIC RECURRENT PERICARDITIS; LOW DRUG DOSE; MALE; PENETRANCE; PERICARDITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; SOUTHERN EUROPE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

EID: 76349123818     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200421     Document Type: Article

References (31)

1. Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol 2006; 98:267-71.
2. Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739-44.
3. Dabestani A, Noble LM, Child JS, Krivokapich J, Schwabe AD. Pericardial disease in familial Mediterranean fever: an echocardiographic study. Chest 1982; 81:592-5.
4. Ozen S, Hoffman HM, Frenkel J, Kastner D. Familial Mediterranean fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6-10 November 2005. Ann Rheum Dis 2006; 65:961-4.
5. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133-44.
6. Dodé C, André M, Bienvenu T, et al; French Hereditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46:2181-8.
7. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81:349-68.
8. McDermott EM, Smillie DM, Powell RJ. Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin Proc 1997; 72:806-17.
9. Spodick DH. The pericardium: a comprehensive textbook. New York: Marcel Dekker; 1997. p. 260-90.
10. Lange RA, Hillis LD. Acute pericarditis. N Engl J Med 2004; 351:2195-202.
11. Tutar EH, Imamoglu A, Atalay S. Recurrent pericarditis as a manifestation of familial Mediterranean fever. Circulation 2000; 101:E71-2.
12. Tunca M, Akar S, Onen F, et al; Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84:1-11.
13. Brucato A, Shinar Y, Brambilla G, et al. Idiopathic recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients. Lupus 2005; 14:670-4.
14. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314:1001-5.
15. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115:1-20.
16. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73:431-45.
17. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351-4.
18. Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301-14.
19. Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108:1320-7.
20. Nedjai B, Hitman GA, Yousaf N, et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:273-83.
21. D'Osualdo A, Ferlito F, Prigione I, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis - Pathogenetic and clinical implications. Arthritis Rheum 2006; 54:998-1008.
22. Nedjai B, Hitman GA, Quillinan N, et al. Proinflammatory action of the anti-inflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009; 60:619-25.
23. Ravet N, Rouaghe S, Dodé C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65:1158-62.
24. Trost S, Rosé CD. Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 2005; 32:175-7.
25. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (Colchicine for Recurrent pericarditis) trial. Arch Intern Med 2005; 165:1987-91.
26. Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004; 5: 289-93.
27. Kallinich T, Briese S, Roesler J, et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 2004; 31:2519-22.
28. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003; 42: 235-9.
29. Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): An unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60:264-8.
30. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007; 66:1545-6.
31. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Runin BI, et al. Neonatal-onset multisystem inflammatory diseases responsive to interleukin-1 inhibition. N Engl J Med 2006; 355: 581-92.